Beth M. Beadle

Beth M. Beadle

Auto-generated profile, based on publicly available information

Beth M. Beadle

Stanford University Stanford California USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JGJessica L. Geiger
Jessica L. Geiger
NINofisat Ismaila
Nofisat Ismaila
BBBeth Beadle
Beth Beadle
JCJimmy J. Caudell
Jimmy J. Caudell
NCNicole Chau
Nicole Chau
Patrick HaPatrick Ha
Patrick Ha
PURPOSE: To provide evidence-based recommendations for practicing physicians and other healthcare providers on the management of salivary gland malignancy.METHODS: ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, neuroradiology, pathology, and patient advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2020. Outcomes of interest included survival, diagnostic accuracy, disease recurrence, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.RESULTS: The literature search identified 293 relevant studies to inform the evidence base for this guideline. Six main clinical questions were addressed, which included subquestions on preoperative evaluations, surgical diagnostic and therapeutic procedures, appropriate radiotherapy techniques, the role of systemic therapy, and follow-up evaluations.RECOMMENDATIONS: When possible, evidence-based recommendations were developed to address the diagnosis and appropriate preoperative evaluations for patients with a salivary gland malignancy, therapeutic procedures, and appropriate treatment options in various salivary gland histologies. Additional information is available at www.asco.org/head-neck-cancer-guidelines .

13 January 2014 in Cancer
Verified
Journal Article
Open access
PDF file
BBBeth M. Beadle
Beth M. Beadle
KLKai‐Ping Liao
Kai‐Ping Liao
LELinda S. Elting
Linda S. Elting
TBThomas Buchholz
Thomas Buchholz
KAK. Kian Ang
K. Kian Ang
BGB. Ashleigh Guadagnolo
B. Ashleigh Guadagnolo
BACKGROUND: Intensity‐modulated radiation therapy (IMRT) is a technologically advanced, and more expensive, method of delivering radiation therapy with a goal of minimizing toxicity. It has been widely adopted for head and neck cancers; however, its comparative impact on cancer control and survival remains unknown. The goal of this analysis was to compare the cause‐specific survival (CSS) for patients with head and neck cancers treated with IMRT versus non‐IMRT from 1999 to 2007.METHODS: CSS was determined using the Surveillance, Epidemiology, and End Results (SEER)‐Medicare database and analyzed regarding treatment details, including the use of IMRT versus non‐IMRT, using claims data. Hazard ratios (HRs) were estimated by the frailty model with a propensity score matching cohort and instrumental variable analysis.RESULTS: A total of 3172 patients were identified. With a median follow‐up of 40 months, patients treated with IMRT had a statistically significant improvement in CSS compared with those treated with non‐IMRT (84.1% versus 66.0%; P < .001). When each anatomic subsite was analyzed separately, all respective subgroups of patients treated with IMRT had better CSS than those treated with non‐IMRT. In multivariable survival analyses, patients treated with IMRT were associated with better CSS (HR = 0.72, 95% confidence interval = 0.59 to 0.90 for propensity score matching; HR = 0.60, 95% confidence interval = 0.41 to 0.88 for instrumental variable analysis).CONCLUSIONS: Patients with head and neck cancers who were treated with IMRT experienced significant improvements in CSS compared with patients treated with non‐IMRT techniques. This suggests there may be benefits to IMRT in cancer outcomes, in addition to toxicity reduction, for this patient population. Cancer 2014;120:702–710. © 2013 American Cancer Society.

29 January 2013 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
AGAdam S Garden
Adam S Garden
MKMerrill S Kies
Merrill S Kies
WMWilliam H Morrison
William H Morrison
RWRandal S Weber
Randal S Weber
SFSteven J Frank
Steven J Frank
ESErich M Sturgis
Erich M Sturgis
We performed this study to assess outcomes of patients with oropharyngeal cancer treated with modern therapy approaches. Demographics, treatments and outcomes of patients diagnosed with Stage 3- 4B squamous carcinoma of the oropharynx, between 2000 – 2007 were tabulated and analyzed. The cohort consisted of 1046 patients. The 5- year actuarial overall survival, recurrence-free survival and local-regional control rates for the entire cohort were 78%, 77% and 87% respectively. More advanced disease, increasing T-stage and smoking were associated with higher rates of local-regional recurrence and poorer survival. Patients with locally advanced oropharyngeal cancer have a relatively high survival rate. Patients’ demographics and primary tumor volume were very influential on these favorable outcomes. In particular, patients with small primary tumors did very well even when treatment was not intensified with the addition of chemotherapy.

1 January 2011 in Seminars in Radiation Oncology
Verified
Journal Article
Closed access
BBBeth M. Beadle
Beth M. Beadle
WWWendy A. Woodward
Wendy A. Woodward
TBThomas A. Buchholz
Thomas A. Buchholz

26 June 2023 in IEEE Transactions on Pattern Analysis and Machine Intelligence
Verified
Journal Article
Closed access
YCYizheng Chen
Yizheng Chen
LYLequan Yu
Lequan Yu
JWJen-Yeu Wang
Jen-Yeu Wang
NPNeil Panjwani
Neil Panjwani
JOJean-Pierre Obeid
Jean-Pierre Obeid
Lei XingLei Xing
Lei Xing
Defining the loss function is an important part of neural network design and critically determines the success of deep learning modeling. A significant shortcoming of the conventional loss functions is that they weight all regions in the input image volume equally, despite the fact that the system is known to be heterogeneous (i.e., some regions can achieve high prediction performance more easily than others). Here, we introduce a region-specific loss to lift the implicit assumption of homogeneous weighting for better learning. We divide the entire volume into multiple sub-regions, each with an individualized loss constructed for optimal local performance. Effectively, this scheme imposes higher weightings on the sub-regions that are more difficult to segment, and vice versa. Furthermore, the regional false positive and false negative errors are computed for each input image during a training step and the regional penalty is adjusted accordingly to enhance the overall accuracy of the prediction. Using different public and in-house medical image datasets, we demonstrate that the proposed regionally adaptive loss paradigm outperforms conventional methods in the multi-organ segmentations, without any modification to the neural network architecture or additional data preparation.

1 May 2015 in Practical Radiation Oncology
Verified
Journal Article
Closed access
VTVinita Takiar
Vinita Takiar
KVK. Ranh Voong
K. Ranh Voong
DGDan Gombos
Dan Gombos
FMFiras Mourtada
Firas Mourtada
LRLaura A. Rechner
Laura A. Rechner
BBBeth M. Beadle
Beth M. Beadle